Cytokinetics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	87.21	18.47	7.53	7.59	70.43	55.83
Other Revenue	-	-	-	87	-	-
Revenue	87.21	18.47	7.53	94.59	70.43	55.83
Revenue Growth (YoY)	2609.26%	145.34%	-92.04%	34.30%	26.15%	107.79%
Cost of Revenue	405.26	339.41	330.12	240.81	159.94	96.95
Gross Profit	-318.05	-320.93	-322.59	-146.23	-89.51	-41.12
Selling, General & Admin	254.89	215.31	173.61	177.98	96.8	52.82
Operating Expenses	254.89	215.31	173.61	177.98	96.8	52.82
Operating Income	-572.93	-536.25	-496.21	-324.2	-186.31	-93.94
Interest Expense	-96.13	-86.51	-57.67	-51.16	-29.33	-38.68
Interest & Investment Income	51.96	51.53	27.63	11.34	0.33	5.33
Other Non Operating Income (Expenses)	-134.85	-18.3	-	-	-	-
EBT Excluding Unusual Items	-751.94	-589.53	-526.24	-364.02	-215.31	-127.29
Other Unusual Items	-	-	-	-24.94	-	-
Pretax Income	-751.94	-589.53	-526.24	-388.96	-215.31	-127.29
Net Income	-751.94	-589.53	-526.24	-388.96	-215.31	-127.29
Net Income to Common	-751.94	-589.53	-526.24	-388.96	-215.31	-127.29
Shares Outstanding (Basic)	119	112	97	90	77	65
Shares Outstanding (Diluted)	119	112	97	90	77	65
Shares Change (YoY)	11.00%	16.01%	7.46%	16.83%	19.16%	12.07%
EPS (Basic)	-6.32	-5.26	-5.45	-4.33	-2.80	-1.97
EPS (Diluted)	-6.32	-5.26	-5.45	-4.33	-2.80	-1.97
Free Cash Flow	-453.38	-399.8	-415.75	-310.85	-191.39	-2.11
Free Cash Flow Per Share	-3.81	-3.57	-4.31	-3.46	-2.49	-0.03
Gross Margin	-	-	-	-154.59%	-127.09%	-73.66%
Operating Margin	-656.95%	-2902.72%	-6589.71%	-342.75%	-264.54%	-168.27%
Profit Margin	-862.21%	-3191.11%	-6988.63%	-411.21%	-305.72%	-228.00%
Free Cash Flow Margin	-519.87%	-2164.10%	-5521.23%	-328.64%	-271.76%	-3.78%
EBITDA	-563.29	-526.72	-484.31	-318.39	-184.04	-92.11
EBITDA Margin	-	-	-	-	-261.31%	-164.99%
D&A For EBITDA	9.65	9.53	11.89	5.81	2.28	1.83
EBIT	-572.93	-536.25	-496.21	-324.2	-186.31	-93.94
EBIT Margin	-	-	-	-	-264.54%	-168.27%
Revenue as Reported	87.21	18.47	7.53	94.59	70.43	55.83

Source: S&P Global Market Intelligence. Standard template. Financial Sources.